CA2776790A1 - Pharmaceutical preparation comprising recombinant hcg - Google Patents

Pharmaceutical preparation comprising recombinant hcg Download PDF

Info

Publication number: CA2776790A1
Authority: CA; Canada
Prior art keywords: sialylation; hcg; mol; rhcg; alpha
Prior art date: 2009-10-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA2776790A

Other languages

English (en)

French (fr)

Inventor

Ian Cottingham

Daniel Plaksin

Richard Boyd White

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ferring BV

Original Assignee

Ferring BV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-05

Filing date

2010-10-04

Publication date

2011-04-14

2010-10-04 Application filed by Ferring BV filed Critical Ferring BV

2011-04-14 Publication of CA2776790A1 publication Critical patent/CA2776790A1/en

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Toxicology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA2776790A 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg Pending CA2776790A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09252360		2009-10-05
EP09252360.4		2009-10-05
PCT/GB2010/001854 WO2011042688A1 (en)	2009-10-05	2010-10-04	Pharmaceutical preparation comprising recombinant hcg

Publications (1)

Publication Number	Publication Date
CA2776790A1 true CA2776790A1 (en)	2011-04-14

Family

ID=41471027

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2776790A Pending CA2776790A1 (en)	2009-10-05	2010-10-04	Pharmaceutical preparation comprising recombinant hcg

Country Status (25)

Country	Link
US (5)	US8975226B2 (2)
EP (2)	EP3611185B1 (2)
JP (6)	JP6176924B2 (2)
KR (7)	KR20230012104A (2)
CN (1)	CN107050434B (2)
AR (2)	AR079876A1 (2)
AU (1)	AU2010304922B2 (2)
BR (1)	BR112012007990A2 (2)
CA (1)	CA2776790A1 (2)
DK (1)	DK2486051T3 (2)
ES (2)	ES2798258T3 (2)
HR (1)	HRP20200941T1 (2)
HU (1)	HUE050793T2 (2)
IL (3)	IL218548A (2)
IN (1)	IN2012DN02073A (2)
JO (1)	JOP20200039A1 (2)
LT (1)	LT2486051T (2)
MX (1)	MX2012003951A (2)
PL (1)	PL2486051T3 (2)
PT (1)	PT2486051T (2)
RS (1)	RS60413B1 (2)
RU (2)	RU2588650C2 (2)
SI (1)	SI2486051T1 (2)
TW (2)	TWI532495B (2)
WO (1)	WO2011042688A1 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI488640B (zh) *	2008-04-16	2015-06-21	菲瑞茵國際中心股份有限公司	藥學製劑
TWI532495B (zh) *	2009-10-05	2016-05-11	菲瑞茵國際中心股份有限公司	藥學製劑
US9757469B2 (en)	2011-03-31	2017-09-12	Ferring B.V.	Pharmaceutical preparation
EP2717904A1 (en) *	2011-06-06	2014-04-16	Ferring BV	Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) *	2011-08-08	2017-03-15	Ferring Bv	مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) *	2011-12-19	2013-06-27	Grifols, S.A.	Compositions, methods, and kits for preparing sialylated recombinant proteins
WO2014092079A1 (ja)	2012-12-10	2014-06-19	生化学工業株式会社	新規組換えファクターｃ、その製造法、およびエンドトキシンの測定法
EP3237608B1 (en) *	2014-12-22	2019-10-09	F. Hoffmann-La Roche AG	Cmp-dependent sialidase activity
LT3286209T (lt) *	2015-04-24	2021-02-25	Ferring Bv	Gonadotropino gamybos būdas
WO2016207353A1 (en) *	2015-06-26	2016-12-29	Ferring B.V.	Methods of purification and/or viral inactivation
RS66871B1 (sr) *	2018-04-30	2025-06-30	Ferring Bv	Kompozicija za kontrolisanu stimulaciju jajnika
US20210244821A1 (en) *	2020-02-05	2021-08-12	Novartis Ag	Cho cell expressed het il-15
CN116199742B (zh) *	2022-07-06	2025-01-24	华兰基因工程有限公司	一种重组人绒毛膜促性腺激素Fc融合蛋白制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4840896A (en) *	1983-11-02	1989-06-20	Integrated Genetics, Inc.	Heteropolymeric protein
DK49987A (da)	1987-01-30	1988-07-31	Nordisk Gentofte	Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it)	1987-06-26	1989-04-14	Serono Cesare Ist Ricerca	Ormone follicolo-stimolante urinario
WO1996029095A1 (en) *	1995-03-21	1996-09-26	Applied Research Systems Ars Holding N.V.	Hcg liquid formulations
IL122732A0 (en) *	1997-01-15	1998-08-16	Akzo Nobel Nv	Liquid gonadotropin-containing formulation its preparation and a device containing same
SI0996629T1 (sl)	1997-06-25	2006-12-31	Applied Research Systems	Analogi glikoproteinskega hormona povezanega z disulfidi, priprava in uporaba
US6500627B1 (en) *	1998-02-03	2002-12-31	The Trustees Of Columbia University In The City Of New York	Methods for predicting pregnancy outcome in a subject by HCG assay
WO2003050286A1 (en) *	2001-10-29	2003-06-19	Crucell Holland B.V.	Methods and means for producing proteins with predetermined post-translational modifications
PT1176976E (pt)	1999-05-07	2006-11-30	Applied Research Systems	Utilização de lh administrada na fase folicular média e tardia para o tratamento de mulheres anovulatórias.
IL151308A0 (en) *	2000-02-22	2003-04-10	Applied Research Systems	PURIFICATION OF hCG AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EA009330B1 (ru)	2001-09-12	2007-12-28	Апплайд Резеч Системз Арс Холдинг Н.В.	Способ содействия имплантации и/или снижения частоты выкидышей и набор для его осуществления
ES2261740T3 (es) *	2001-10-22	2006-11-16	Applied Research Systems Ars Holding N.V.	Composiciones de fsh con alto grado de sialilacion y su uso para la preparacion de medicamentos.
CA2756610C (en) *	2001-10-29	2015-08-25	Crucell Holland B.V.	Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
CN1374525A (zh) *	2001-12-31	2002-10-16	陕西超英生物医学研究开发有限公司	一种抗体芯片、其制备技术及其检测方法
MXPA05010373A (es)	2003-04-01	2005-12-05	Applied Research Systems	Inhibidores de fosfodiesterasas en infertilidad.
EP2055189A1 (en) *	2003-04-09	2009-05-06	Neose Technologies, Inc.	Glycopegylation methods and proteins/peptides produced by the methods
US20040248784A1 (en)	2003-06-03	2004-12-09	Marco Filicori	Unitary combinations of FSH and hCG
JP4518464B2 (ja)	2003-06-30	2010-08-04	ミヨシ油脂株式会社	紙類処理剤及び紙類
ES2425475T3 (es) *	2003-08-18	2013-10-15	Glycotope Gmbh	Líneas de células tumorales NM-F9 (DSM ACC2606) y NM-D4 (DSM ACC2605), usos de las mismas
DE602005022675D1 (de) *	2004-02-04	2010-09-16	Centre Nat Rech Scient	Verfahren zur identifizierung von glykoformspezifischen antikörpern
EP1725673A1 (en) *	2004-02-13	2006-11-29	Glycotope Gmbh	Sialytated glycoproteins-process conditions and an efficient method for their production
AU2006222187A1 (en) *	2005-03-11	2006-09-14	Fresenius Kabi Deutschland Gmbh	Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
JP2009504985A (ja) *	2005-08-15	2009-02-05	シーメンスヴィディーオーオートモーティヴコーポレイション	ディーゼル車排気への炭化水素計量弁
RU2309411C2 (ru) *	2005-11-24	2007-10-27	Ростовский НИИ акушерства и педиатрии МЗ РФ	Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) *	2006-02-01	2008-03-05	대한민국	인체장내정상세균총 특이반응 ｄｎａ칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
ES2516694T3 (es) *	2006-07-21	2014-10-31	Ratiopharm Gmbh	Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
US8969532B2 (en) *	2006-10-03	2015-03-03	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
TWI488640B (zh)	2008-04-16	2015-06-21	菲瑞茵國際中心股份有限公司	藥學製劑
TWI532495B (zh)	2009-10-05	2016-05-11	菲瑞茵國際中心股份有限公司	藥學製劑
US9757469B2 (en) *	2011-03-31	2017-09-12	Ferring B.V.	Pharmaceutical preparation
JO3092B1 (ar) *	2011-08-08	2017-03-15	Ferring Bv	مركب لتحفيز مسيطر عليه للمبيض

2010
- 2010-09-27 TW TW099132570A patent/TWI532495B/zh not_active IP Right Cessation
- 2010-09-27 TW TW104140348A patent/TWI604850B/zh active
- 2010-10-04 ES ES10763000T patent/ES2798258T3/es active Active
- 2010-10-04 BR BR112012007990A patent/BR112012007990A2/pt not_active Application Discontinuation
- 2010-10-04 EP EP19190372.3A patent/EP3611185B1/en active Active
- 2010-10-04 WO PCT/GB2010/001854 patent/WO2011042688A1/en not_active Ceased
- 2010-10-04 IN IN2073DEN2012 patent/IN2012DN02073A/en unknown
- 2010-10-04 KR KR1020237001308A patent/KR20230012104A/ko active Pending
- 2010-10-04 KR KR1020217037028A patent/KR102489143B1/ko active Active
- 2010-10-04 CN CN201610832288.8A patent/CN107050434B/zh active Active
- 2010-10-04 KR KR1020127008827A patent/KR101804479B1/ko active Active
- 2010-10-04 US US13/500,274 patent/US8975226B2/en active Active
- 2010-10-04 RS RS20200698A patent/RS60413B1/sr unknown
- 2010-10-04 KR KR1020197016021A patent/KR102213154B1/ko active Active
- 2010-10-04 RU RU2012112907/10A patent/RU2588650C2/ru active
- 2010-10-04 CA CA2776790A patent/CA2776790A1/en active Pending
- 2010-10-04 HU HUE10763000A patent/HUE050793T2/hu unknown
- 2010-10-04 LT LTEP10763000.6T patent/LT2486051T/lt unknown
- 2010-10-04 PL PL10763000T patent/PL2486051T3/pl unknown
- 2010-10-04 EP EP10763000.6A patent/EP2486051B1/en active Active
- 2010-10-04 PT PT107630006T patent/PT2486051T/pt unknown
- 2010-10-04 MX MX2012003951A patent/MX2012003951A/es active IP Right Grant
- 2010-10-04 KR KR1020197007226A patent/KR101987982B1/ko not_active Expired - Fee Related
- 2010-10-04 AU AU2010304922A patent/AU2010304922B2/en active Active
- 2010-10-04 KR KR1020177034392A patent/KR20170133531A/ko not_active Withdrawn
- 2010-10-04 HR HRP20200941TT patent/HRP20200941T1/hr unknown
- 2010-10-04 KR KR1020217003233A patent/KR20210014767A/ko not_active Ceased
- 2010-10-04 ES ES19190372T patent/ES3036152T3/es active Active
- 2010-10-04 RU RU2016118236A patent/RU2724528C2/ru active
- 2010-10-04 DK DK10763000.6T patent/DK2486051T3/da active
- 2010-10-04 JP JP2012532657A patent/JP6176924B2/ja active Active
- 2010-10-04 SI SI201032015T patent/SI2486051T1/sl unknown
- 2010-10-05 AR ARP100103608A patent/AR079876A1/es not_active Application Discontinuation
2012
- 2012-03-08 IL IL218548A patent/IL218548A/en active IP Right Grant
2014
- 2014-05-21 US US14/283,904 patent/US9676835B2/en active Active
2015
- 2015-11-09 JP JP2015219480A patent/JP6310440B2/ja active Active
2017
- 2017-02-23 IL IL250733A patent/IL250733B/en active IP Right Grant
- 2017-05-03 US US15/586,010 patent/US10526390B2/en active Active
- 2017-10-24 JP JP2017205012A patent/JP6580104B2/ja active Active
2019
- 2019-06-20 IL IL267556A patent/IL267556A/en unknown
- 2019-08-27 JP JP2019154226A patent/JP7292153B2/ja active Active
- 2019-12-10 US US16/709,810 patent/US11292824B2/en active Active
2020
- 2020-02-17 JO JOP/2020/0039A patent/JOP20200039A1/ar unknown
2021
- 2021-07-12 JP JP2021114833A patent/JP7196244B2/ja active Active
2022
- 2022-03-30 US US17/709,296 patent/US12234272B2/en active Active
- 2022-05-27 AR ARP220101408A patent/AR125991A2/es not_active Application Discontinuation
2023
- 2023-02-22 JP JP2023025781A patent/JP2023075144A/ja active Pending

Also Published As

Publication number	Publication date
JP6310440B2 (ja)	2018-04-11
US20200247863A1 (en)	2020-08-06
US20180030107A1 (en)	2018-02-01
KR20230012104A (ko)	2023-01-25
JP2020000246A (ja)	2020-01-09
KR102213154B1 (ko)	2021-02-05
RU2016118236A3 (2)	2019-09-18
HRP20200941T1 (hr)	2020-09-18
KR20190067256A (ko)	2019-06-14
JP7292153B2 (ja)	2023-06-16
KR101987982B1 (ko)	2019-06-11
ES2798258T3 (es)	2020-12-10
KR20190028823A (ko)	2019-03-19
TW201113030A (en)	2011-04-16
IL267556A (en)	2019-08-29
JP2013506708A (ja)	2013-02-28
US8975226B2 (en)	2015-03-10
IL218548A (en)	2017-03-30
AR079876A1 (es)	2012-02-29
PT2486051T (pt)	2020-06-17
JP2018076296A (ja)	2018-05-17
JP7196244B2 (ja)	2022-12-26
ES3036152T3 (en)	2025-09-15
AU2010304922B2 (en)	2014-11-06
IL218548A0 (en)	2012-05-31
HUE050793T2 (hu)	2021-01-28
WO2011042688A1 (en)	2011-04-14
US20220340634A1 (en)	2022-10-27
JP6580104B2 (ja)	2019-09-25
EP3611185A1 (en)	2020-02-19
KR20170133531A (ko)	2017-12-05
SI2486051T1 (sl)	2020-08-31
KR20210141771A (ko)	2021-11-23
US20140249082A1 (en)	2014-09-04
CN107050434B (zh)	2021-07-27
JP2016074680A (ja)	2016-05-12
IN2012DN02073A (2)	2015-08-21
US9676835B2 (en)	2017-06-13
US10526390B2 (en)	2020-01-07
RS60413B1 (sr)	2020-07-31
BR112012007990A2 (pt)	2017-07-25
JP2021176867A (ja)	2021-11-11
US12234272B2 (en)	2025-02-25
KR101804479B1 (ko)	2017-12-05
US11292824B2 (en)	2022-04-05
JP6176924B2 (ja)	2017-08-09
TW201632198A (zh)	2016-09-16
KR20120094909A (ko)	2012-08-27
TWI604850B (zh)	2017-11-11
PL2486051T3 (pl)	2020-09-07
EP2486051A1 (en)	2012-08-15
EP3611185B1 (en)	2025-04-30
RU2724528C2 (ru)	2020-06-23
RU2588650C2 (ru)	2016-07-10
KR20210014767A (ko)	2021-02-09
CN102549011A (zh)	2012-07-04
RU2016118236A (ru)	2018-10-29
RU2012112907A (ru)	2013-11-10
IL250733B (en)	2019-07-31
US20130023476A1 (en)	2013-01-24
CN107050434A (zh)	2017-08-18
JP2023075144A (ja)	2023-05-30
MX2012003951A (es)	2012-05-29
AU2010304922A1 (en)	2012-03-29
AR125991A2 (es)	2023-08-30
LT2486051T (lt)	2020-07-10
IL250733A0 (en)	2017-04-30
KR102489143B1 (ko)	2023-01-13
EP2486051B1 (en)	2020-03-25
DK2486051T3 (da)	2020-06-22
JOP20200039A1 (ar)	2022-10-30
TWI532495B (zh)	2016-05-11

Legal Events

Date	Code	Title	Description
2015-10-16	EEER	Examination request	Effective date: 20150930
2024-10-01	MFA	Maintenance fee for application paid	Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 14TH ANNIV.) - STANDARD Year of fee payment: 14
2024-10-01	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241001
2024-10-01	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241001 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241001
2025-02-17	D15	Examination report completed	Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250217
2025-06-17	B12	Application deemed to be withdrawn, abandoned or lapsed	Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20250617
2025-11-17	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251117

Publication	Publication Date	Title
US12234272B2 (en)	2025-02-25	Pharmaceutical preparation comprising recombinant HCG
CA2725257A1 (en)	2009-10-22	Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP2691119B1 (en)	2018-08-01	Pharmaceutical preparation
HK40020346A (en)	2020-10-23	Pharmaceutical preparation
CN102549011B (zh)	2016-12-14	包含重组hcg的药物制剂
HK1174338A (en)	2013-06-07	Pharmaceutical preparation comprising recombinant hcg
HK1174338B (en)	2021-01-08	Pharmaceutical preparation comprising recombinant hcg
Class et al.	2014	Patent application title: Pharmaceutical Preparation Comprising Recombinant HcG Inventors: Ian Cottingham (St. Prex, CH) Daniel Plaksin (St. Prex, CH) Richard Boyd White (San Diego, CA, US) Assignees: Ferring BV
HK1194281A (en)	2014-10-17	Pharmaceutical preparation
HK1194281B (en)	2019-09-27	Pharmaceutical preparation